Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6997539 | 1.00 | GBA1 (0.46) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL500387 | 0.92 | FUCA1 (0.55) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL10511264 | 0.92 | FUCA1 (0.55) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL18453619 | 0.89 | PTPN1 (0.44) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL22211395 | 0.89 | PTPN1 (0.44) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL500407 | 0.89 | PTPN1 (0.44) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL18488954 | 0.89 | PTPN1 (0.44) | GBA1FUCA1RECQLSMN1; SMN2PTPN1 | |
| SCHEMBL3917962 | 0.85 | FUCA1 (0.43) | FUCA1RECQLSMN1; SMN2PTPN1S1PR1 | |
| SCHEMBL3917960 | 0.85 | FUCA1 (0.43) | FUCA1RECQLSMN1; SMN2PTPN1S1PR1 | |
| SCHEMBL17220043 | 0.85 | FUCA1 (0.43) | FUCA1RECQLSMN1; SMN2PTPN1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022210-B1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2018-02-21 | — | — | EP | disclosed |
| EP-3022210-B1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9492436-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9492436-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9492436-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| EP-3022210-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| WO-2015007669-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015007669-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | WO | disclosed |
| EP-0792273-B1 | BICYCLIC OXAZINE AND THIAZINE OXAZOLIDINONE ANTIBACTERIALS | UPJOHN CO (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5952324-A | BACTERICIDES AGAINST A NUMBER OF HUMAN AND VETERINARY PATHOGENS, INCLUDING GRAMPOSITIVE AEROBIC BACTERIA SUCH AS STAPHYLOCOCCI, STREPTOCOCCI, ENTEROCOCCI AND ANAEROBIC ORGANISMS SUCH AS BACTEROIDES, CLOSTRIDIA AND MYCOBACTERIUM | PHARMACIA & UPJOHN COMPANY (US) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025065-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB1, PRKAB2 | GBA1 3397/4885FUCA1 3735/4885RECQL 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.